Abstract |
A trial was undertaken to ascertain the effect and acceptability of a multiple insulin injection regimen (MII) in patients with insulin-dependent diabetes mellitus using short-acting monocomponent human soluble insulin (Actrapid HM; Novo) for pre-meal bolus injections with the NovoPen injection device (Novo) and long-acting human insulin (Ultratard HM; Novo) at bedtime. Fifty-four patients, all previously on twice-daily short/intermediate-acting human insulin (Monotard HM; Novo) and Actrapid HM, were randomly selected. There was a significant overall improvement in diabetic control over the 12 weeks of the trial, the glycosylated haemoglobin ( Hb A1) dropping from a mean of 9.8 +/- 2.2% to 8.6 +/- 1.7% (P less than 0.05). MII, using the NovoPen, was found to be more convenient than conventional insulin administration by 92% of the subjects. It is concluded that the NovoPen is a useful and convenient means of administering pre-meal boluses in an MII regimen, with a very high rate of acceptance by patients of all ages.
|
Authors | L A Distiller, L I Robertson, R Moore, F Bonnici |
Journal | South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
(S Afr Med J)
Vol. 71
Issue 12
Pg. 749-52
(Jun 20 1987)
ISSN: 0256-9574 [Print] South Africa |
PMID | 3299758
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Glycated Hemoglobin A
- Insulin
- Insulin, Long-Acting
|
Topics |
- Adolescent
- Adult
- Child
- Clinical Trials as Topic
- Diabetes Mellitus, Type 1
(drug therapy)
- Evaluation Studies as Topic
- Female
- Glycated Hemoglobin
(analysis)
- Humans
- Injections
(instrumentation)
- Insulin
(administration & dosage)
- Insulin, Long-Acting
(administration & dosage)
- Male
- Middle Aged
- Random Allocation
- Time Factors
|